Healthcare company Perrigo Company plc (NYSE:PRGO) (TASE:PRGO) revealed on Wednesday the availability of an AB rated generic version of Epiduo (adapalene and benzoyl peroxide) Gel, 0.1%/2.5% for acne vulgaris.
This launch of the company's AB rated generic version of Epiduo (adapalene and benzoyl peroxide) Gel, 0.1%/2.5% follows the US Food and Drug Administration's (FDA) approval.
The company said Epiduo Gel is indicated for the topical treatment of acne vulgaris in patients nine years of age and older.
According to IMS Health, the market sales of Epiduo Gel over the last 12 months were about USD164m, stated the company.
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US